Canaccord Adams initiates coverage on Transition Therapeutics (Nasdaq: TTHI) with a Buy rating and C$18.40 price ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE